mercredi 20 décembre 2017

Onco Actu du 20 décembre 2017

2.6 Etiologie - Environnement

EPA says herbicide in Roundup weed killer doesn't cause cancer, contradicting California regulators [LA Times]

3. Prévention

Personalised prevention in breast cancer – the policy landscape [PHG]

3.1 Prévention - Tabac

Smoking ban cannot be enforced in jails, UK supreme court rules [The Guardian]

4. Dépistage, diagnostic et pronostic

Cutting cancer diagnosis delays means understanding each patient’s journey [Cancer Research UK]

Too Many Older Patients Get Cancer Screenings [NY Times]

4.12 Biopsies liquides

Oncologists, Beware: Expensive Liquid Biopsy Tests Produce Conflicting Results [Forbes]

4.9 Dép., diag. & prono. - Sein

MRI could detect signs of more aggressive breast cancers [Institute of Cancer Research]

5. Traitements

Combination Rethink [Harvard Medical School]

NIH study uncovers clues about why common cancer drug causes hearing loss [NIH]

5.10 Traitements - Essais

Creating electric fields in the brain buys glioblastoma patients extra months of life [STAT]

Electronic cap treatment improves brain tumour survival [Cancer Research UK]

5.12.1 Immunothérapies - partenariats

Stepping up behind Sanofi, Genentech rolls the DiCE on a new small molecule discovery pact [EndPoints]

5.2 Pharma

AstraZeneca snags Tagrisso 'breakthrough' in first-line EGFR lung cancer patients [FiercePharma]

Is Roche’s pRED finally ready to step out from behind Genentech for its closeup? Probably not [EndPoints]

Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer [Novocure]

5.2.1 Pharma - Partenariats

Array Biopharma ties up with Pfizer on cancer-fighting combos [FierceBiotech]

Array BioPharma Announces Strategic Collaboration with Pfizer [Array]

Array joins Pfizer on anti-cancer combos, the latest in a string of binimetinib combinations [EndPoints]

5.2.3 Pharma - économie

Enticed by tax reform, Pfizer ups dividend, marks $10B for buybacks. Who's next? [FiercePharma]

Pfizer Shareholders Are Already Enjoying the Fruits of Tax Cuts [Bloomberg]

Drug Industry Spent Millions To Squelch Talk About High Drug Prices [KHN]

5.3.4 Traitements - AMM (FDA, EMA)

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma [Exelixis]

U.S. FDA Approves Pfizer’s BOSULIF® (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) [Pfizer]

Pfizer, Exelixis cancer drugs get FDA approval for wider use [Reuters]

5.4 Traitements - Economie

‘Drugs are too expensive for the NHS – and people are paying with their lives’ [The Guardian]

5.5 ASCO

Howard A. “Skip” Burris III, MD, FACP, FASCO, Elected ASCO President for 2019-2020 Term [ASCO]

6. Lutte contre les cancers

Anticipating fundamental change in oncology [The Cancer Letter]

6.10.1 Politiques (USA)

Take Action Now: Urge Congress to Address Three Cancer Policy Priorities by the End of the Year [ASCO]